# Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Non-Small Cell Lung Cancer (NSCLC)

> **NCT01024062** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 60 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT01024062
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-12
- **Primary completion:** 2005-03
- **Final completion:** 2005-03
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2011-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01024062

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01024062, "Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Non-Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01024062. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*